898 results about "Blood specimen" patented technology

An automatic skin puncturing system that was operable with one hand for allowing individuals with the use of only a single hand to take the blood samples needed to monitor their blood glucose levels. The automatic skin puncturing system includes a housing assembly, a power connecting jack, a battery holder, an indexable, motor driven turntable, an index switch, a reed switch, a lancet lifting assembly, a disposable lancet carousel cartridge, and an electronic, micro-processor controlled circuit.

The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.

The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.

The present invention provides methods and compositions for specifically identifying a fetal cell. An initial screening of approximately 400 candidate genes by digital PCR in different fetal and adult tissues identified a subset of 24 gene markers specific for fetal nucleated RBC and trophoblasts. The specific expression of those genes was further evaluated and verified in more defined tissues and isolated cells through quantitative RT-PCR using custom Taqman probes specific for each gene. A subset of fetal cell specific markers (FCM) was tested and validated by RNA fluorescent in situ hybridization (FISH) in blood samples from non-pregnant women, and pre-termination and post-termination pregnant women. Applications of these gene markers include, but are not limited to, distinguishing a fetal cell from a maternal cell for fetal cell identification and genetic diagnosis, identifying circulating fetal cell types in maternal blood, purifying or enriching one or more fetal cells, and enumerating one or more fetal cells during fetal cell enrichment.

A method of inspecting a clinical specimen for a presence of one or more interferents, such as those that might be found within clinical analytical blood specimens by subjecting the specimen to centrifugation to separate the specimen into a red blood cell portion and a blood serum or plasma portion is provided. Subsequent to the centrifuging procedure, the serum or plasma portion of the clinical analytical specimen may be tested for the presence of one or more interferents such as hemolysis, icterus, lipemia, or liquid nonuniformities therein. Additionally, physical dimensional characteristics of the sample container and / or specimen may be determined. Apparatus for carrying out the method are described, as are other aspects.

The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

A method for preserving and processing nucleic acids located within a blood sample is disclosed, wherein a blood sample containing nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the integrity and amount of cellular nucleic acids that can be identified and tested while avoiding contamination of the isolated nucleic acids with cell-free nucleic acids.

The present invention is a programmable, automated device for measurement and analysis of blood analytes and blood parameters. The device components are preferably combined in a single housing and either programmed to initiate automatic, periodic blood sampling or initiate automatic blood sampling via operator input or in response to a predefined event or in response to a signal from another instrument. The device operates automatically to draw blood samples and analyze the drawn blood samples to obtain the desired blood readings.

A kit containing all the materials needed to take a blood sample from a neonatal patient, a pediatric patient, a juvenile patient or an adult patient. The materials are supplied in a plastic package suitable for sterilization.

Compositions and methods for stabilizing rare cells in blood specimens, preserving the quality of blood specimens, and also serving as cell fixatives are disclosed which minimize losses of target cells (for example, circulating tumor cells) and formation of debris and aggregates from target cells, non-target cells and plasma components, thereby allowing more accurate analysis and classification of circulating tumor cells (CTC) and, ultimately, of tumor burdens in cancer patients. Stabilization of specimens is particularly desirable in protocols requiring rare cell enrichment from blood specimens drawn from cancer patients. Exposure of such specimens to potentially stressful conditions encountered, for example, in normal processing, mixing, shaking, delays due to transporting the blood, has been observed to not only diminish the number of CTC but also to generate debris and aggregates in the blood specimens that were found to interfere with accurate enumeration of target cells, if present. Stabilizers are necessary to discriminate between in vivo CTC disintegration and in vitro sample degredation.

A method and apparatus for use in respect of samples which are assessed for quality prior to testing in a clinical analyzer. The method and apparatus identify parameters such as gel level and height of fluid above the gel in blood samples, where appropriate, for the purposes of positioning the specimen for determination of interferents. Such interferents include hemoglobin (Hb), total bilirubin and lipids. These interferents are determined by measurement of absorption of different wavelengths of light in serum or plasma, or other specimens, which are then compared with values obtained through calibration using reference measurements for the respective interferents in serum or plasma or other type of specimen. Determinations of temperature of the specimen, as well as specimen type, for example whether the specimen is urine or plasma or serum, may also be carried out.

The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.

A blood sampling device useful for collecting a blood sample from a separate vascular access device is described herein. The blood sampling device includes a body shaped and sized for partial insertion into a separate vascular access device. The body includes a reservoir defined within the body, which has an internal volume sufficient to contain enough blood for use in a diagnostic blood test. The body also includes a gas permeable vent disposed on the body, in which the gas permeable vent is in gaseous communication with the reservoir. When connected to a separate vascular access device the blood sampling device collects a blood sample as blood flows into the reservoir from the separate vascular access device and as gases pass out the reservoir via the gas permeable vent.

A novel reagent system for use with automated and semi-automated hematology analyzers including an essentially isotonic blood diluting reagent, a blood cell lysing and hemoglobin conversion reagent, and a second lysing reagent for differentiating white blood cells into classes by size and functional characteristics. The diluent reagent enhances properties for counting and sizing blood specimens, while stabilizing cellular volume and cellular integrity for many hours. The blood cell lysing reagent removes red blood cells and enables subsequent enumeration of white blood cells and simultaneous determination of hemoglobin without use of the toxic cyanide anion. The third lysing reagent and a companion quenching differentiates blood cells into classes by size and functional characteristics, based on d.c. impedance volume, conductivity / opacity and light scatter measurements. The companion quenching reagent adjusts pH and conductivity of the final measurement solution to match the analyzer system requirements. Novel methods for use of the reagents with automated and semi-automated hematology analyzers are also provided.< / PTEXT>

The present invention relates to a hematology instrument system that discriminates platelets from red blood cells, debris and other particles within a blood sample. The instrument system uses an optical trigger and collects data at optical sensor locations relative to a flow cell-illuminating laser beam's optical axis. An axial sensor measures axial light loss due to a particle in the flow cell's illumination aperture. In addition, the instrument system can include an RF unit generates electrical parameters, such as DC and RF parameters, within the flow cell. Blood specimens can be prepared with and without a sphering agent.

The invention discloses a whole blood DNA (deoxyribonucleic acid) extraction kit based on a paramagnetic particle method and an application of the extraction kit. The kit comprises a cell lysis solution, a binding solution, a washing solution I, a washing solution II and a nucleic acid eluent. Compared with kits in the prior art, the kit has the advantages of simple and quick operation, use safety, high extraction efficiency, low manufacturing cost and the like; no toxic reagents or organic solvents are used when the kit is used, a blood sample is not required to be pre-treated, the extraction process can be finished manually and can also be automatically finished in a full-automatic nucleic acid extraction instrument, 1-16 animal tissue samples can be treated each time with a 96-hole reaction plate during automatic extraction, other operation is not required in the extraction process, time is saved for whole blood DNA extraction and detection, and the cost is reduced; DNA in the blood can be quickly extracted with the adoption of the kit, the concentration and the purity of extracted nucleic acid are high, the repeatability is good, and the kit can be used for scientific research and clinical detection.

The invention provides a blood sugar biosensor of carbon nanometer tube, it includes floor, three electrode system, insulation, forming the reaction lumen body around three electrode system, setting the conversion zone in the reaction lumen body, laying over the cover plate on the reaction lumen body, the conversion zone includes, enzyme and electron transport agent, the enzyme is the glc dh pyrrole and quinone for coenzyme. The transducer's corresponding sensitivity improves evidently, it has not infection for measuring the dextrose deepness in the blood with the oxygen pressure, thickness in the measuring site and oxygen content of blood sample. The invention has the excellence of easy manufacture artwork, low cost, suited to volume-produce and the low sample quantity etc.

A system for the collection, treatment and delivery of an autologous blood sample, comprising a first syringe for drawing an untreated blood sample from a patient, a blood sample treatment chamber having a chamber inlet for receiving untreated blood from the first syringe and chamber outlet for passage of treated blood to a second syringe coupled thereto. The second syringe includes a releasable lock means for allowing discharge of the treated blood to the patient in response to a release signal. The release signal is issued following a positive outcome from a verification process dependent upon temporal data from certain events in the collection, treatment and delivery of the blood sample, and identity data of the patient and the second syringe with the treated blood.

A blood recipient verification device includes a patient ID label region including a top ID label layer on which information can be imprinted, a bottom layer comprising an image material in underlining registry with the top layer, an elongate strap adjacent the patient ID label region, and an identification label region that is removably attached to either an end of the patient ID label region or an end of the elongate strap. At least a portion of the elongate strap may be transparent so as to provide a window through which information on the bottom layer can be read while protecting such information from being damaged. An adhesive coating may be applied to the same surface as the removable identification labels of the identification label region so that when the labels are affixed to a blood sample collection tube, the labels will not be exposed but be protected.

The invention relates to a hemolytic agent for blood leukocyte five-classification counting and an application thereof. The hemolytic agent comprises a hemolytic agent A and a hemolytic agent B. The hemolytic agent A comprises a polyoxyethylene nonionic surfactant, an organic acid, a quaternary ammonium salt cationic surfactant cosolvent, a stabilizing agent and an osmotic regulator; the hemolytic agent B comprises alkaline inorganic salt and an osmotic regulator. When compared with the result detected by a standard hemolytic agent produced by BeckmanCoulter company, the hemolytic agent of the invention has good correlation and high accuracy. Especially, when abnormal cells exist in a blood specimen, the hemolytic agent has high warning sensitivity and good specificity, and exhibits the most beneficial effect.

A platform or workstation comprising a plurality of various size holes and slots for holding blood specimens, test tubes, gel-cards and reagent bottles in an organized arrangement to simplify testing of the blood specimens and to eliminate the likelihood of human error. The platform comprises a top plate, a middle plate and a bottom plate which are spaced apart in a parallel plates arrangement. The top plate and the middle plate each comprise a plurality of holes in a matrix configuration for receiving blood specimen tubes and test tubes, and one or more columns of slots adjacent to the matrix configuration of holes for receiving gel-cards. Other size holes are provided for receiving the reagent bottles. The bottom plate only has screw holes for securing the top plate, middle plate and bottom plate together in the spaced apart relationship, and otherwise performs as a stop for articles inserted into the workstation holes. A first embodiment organizes all equipment needed to perform routine and complex testing in one space using 70 holes of 3 sizes and 3 slots in a predetermined arrangement. A second embodiment organizes blood specimens, test tubes and gel-cards in a row and stores reagents needed to perform tests using 57 holes of 3 sizes and 16 slots in a predetermined arrangement. A third embodiment organizes equipment for special studies and tests and uses 35 holes of 3 sizes and 12 slots in a predetermined arrangement.

The present invention relates to a hematology instrument system that discriminates platelets from red blood cells, debris and other particles within a blood sample. The instrument system uses an optical trigger and collects data at optical sensor locations relative to a flow cell-illuminating laser beam's optical axis. An axial sensor measures axial light loss due to a particle in the flow cell's illumination aperture. In addition, the instrument system can include an RF unit generates electrical parameters, such as DC and RF parameters, within the flow cell. Blood specimens can be prepared with and without a sphering agent.

An infusion and blood collection device allows clean blood collections into a collection tube via a previously installed angiocatheter without interrupting the administration of intravenous therapies after initial installation. The device optionally includes passive control of the blood collection flow rate to prevent contamination of the collected blood draw with the IV therapy fluid being simultaneously infused through the angiocatheter. A blood collection method uses an infusion and blood collection device to draw a clean blood sample from a patient and into a collection tube via a previously installed angiocatheter without interrupting the administration of intravenous therapies.